Xeris Biopharma Holdings Statistics
Total Valuation
XERS has a market cap or net worth of $3.06 billion. The enterprise value is $3.15 billion.
Important Dates
The last earnings date was Thursday, November 5, 2026, before market open.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
XERS has 182.70 million shares outstanding. The number of shares has increased by 10.49% in one year.
| Current Share Class | 182.70M |
| Shares Outstanding | 182.70M |
| Shares Change (YoY) | +10.49% |
| Shares Change (QoQ) | +9.89% |
| Owned by Insiders (%) | 3.38% |
| Owned by Institutions (%) | 61.76% |
| Float | 176.52M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 51.81 |
| PS Ratio | 8.25 |
| Forward PS | 6.55 |
| PB Ratio | 62.20 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 41.81 |
| P/OCF Ratio | 41.23 |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
The stock's EV/EBITDA ratio is 53.13, with an EV/FCF ratio of 43.12.
| EV / Earnings | n/a |
| EV / Sales | 8.50 |
| EV / EBITDA | 53.13 |
| EV / EBIT | 66.94 |
| EV / FCF | 43.12 |
Financial Position
The company has a current ratio of 2.15, with a Debt / Equity ratio of 4.63.
| Current Ratio | 2.15 |
| Quick Ratio | 1.48 |
| Debt / Equity | 4.63 |
| Debt / EBITDA | 3.37 |
| Debt / FCF | 3.11 |
| Interest Coverage | 1.70 |
Financial Efficiency
Return on equity (ROE) is -27.11% and return on invested capital (ROIC) is 11.00%.
| Return on Equity (ROE) | -27.11% |
| Return on Assets (ROA) | 7.37% |
| Return on Invested Capital (ROIC) | 11.00% |
| Return on Capital Employed (ROCE) | 16.20% |
| Weighted Average Cost of Capital (WACC) | 8.91% |
| Revenue Per Employee | $846,572 |
| Profits Per Employee | -$14,933 |
| Employee Count | 435 |
| Asset Turnover | 0.93 |
| Inventory Turnover | 0.64 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +135.12% in the last 52 weeks. The beta is 0.84, so XERS's price volatility has been lower than the market average.
| Beta (5Y) | 0.84 |
| 52-Week Price Change | +135.12% |
| 50-Day Moving Average | 11.28 |
| 200-Day Moving Average | 8.07 |
| Relative Strength Index (RSI) | 80.59 |
| Average Volume (20 Days) | 3,370,005 |
Short Selling Information
The latest short interest is 8.99 million, so 4.92% of the outstanding shares have been sold short.
| Short Interest | 8.99M |
| Short Previous Month | 8.03M |
| Short % of Shares Out | 4.92% |
| Short % of Float | 5.09% |
| Short Ratio (days to cover) | 3.80 |
Income Statement
In the last 12 months, XERS had revenue of $368.26 million and -$6.50 million in losses. Loss per share was -$0.04.
| Revenue | 368.26M |
| Gross Profit | 321.80M |
| Operating Income | 46.78M |
| Pretax Income | -6.50M |
| Net Income | -6.50M |
| EBITDA | 58.94M |
| EBIT | 46.78M |
| Loss Per Share | -$0.04 |
Full Income Statement Balance Sheet
The company has $131.08 million in cash and $226.07 million in debt, with a net cash position of -$94.98 million or -$0.52 per share.
| Cash & Cash Equivalents | 131.08M |
| Total Debt | 226.07M |
| Net Cash | -94.98M |
| Net Cash Per Share | -$0.52 |
| Equity (Book Value) | 48.78M |
| Book Value Per Share | 0.27 |
| Working Capital | 154.79M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was $73.65 million and capital expenditures -$1.03 million, giving a free cash flow of $72.62 million.
| Operating Cash Flow | 73.65M |
| Capital Expenditures | -1.03M |
| Depreciation & Amortization | 12.16M |
| Net Borrowing | -23.07M |
| Free Cash Flow | 72.62M |
| FCF Per Share | $0.40 |
Full Cash Flow Statement Margins
Gross margin is 87.38%, with operating and profit margins of 12.70% and -1.76%.
| Gross Margin | 87.38% |
| Operating Margin | 12.70% |
| Pretax Margin | -1.76% |
| Profit Margin | -1.76% |
| EBITDA Margin | 16.00% |
| EBIT Margin | 12.70% |
| FCF Margin | 19.72% |
Dividends & Yields
XERS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -10.49% |
| Shareholder Yield | -10.49% |
| Earnings Yield | -0.22% |
| FCF Yield | 2.39% |
Analyst Forecast
The average price target for XERS is $17.29, which is 3.35% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $17.29 |
| Price Target Difference | 3.35% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 30.01% |
| EPS Growth Forecast (3Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
XERS has an Altman Z-Score of 1.41 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.41 |
| Piotroski F-Score | 7 |